Observation Of The Results In The Treatment Of Percutaneous Radiofrequency Ablation, Transcatheter Arterial Chemoembolization For Hepatocellular Carcinoma

Objective To explore the feasibility, effect, safety and problems of percutaneous radiofrequency ablation,transcatheter arterial chemoembolization and the combined treatment of the two for hepatocellular carcinoma. Methods 96 patients who had primary liver cancer confirmed clinically or pathologically that were located in hepatic were involved in the study from January,2005 to March,2008, including 15 patients who were performed by PRFA, 76 patients who were treated by TACE, and 5 patients who were treated by combining PRFA and TACE. All of the patients were followed up by examining the value of their serous AFP and computerized tomography examination. The remission rate, rate of descend of serous AFP value and 0.5-, 1-, 2-year survival rate in each group were observed. Results (1) In PRFA group, its remission rate was 73.3%, rate of descend of serous AFP value was 58.3%, and 0.5-, 1-, 2-year survival rate was 93.3%, 86.7%, 50.7%, respectively.(2) In TACE group, its Remission rate was 50.0%, rate of descend of serous AFP value was 51.7%, 0.5-, 1-, 2-year survival rate was 88.2%, 61.8%, 28.9% , respectively. (3) In group of combining PRFA and TACE , Remission rate was 80.0%, rate of descend of serous AFP value was 66.7%, 0.5-, 1-, 2-year survival rate was 100.0%, 80.0%, 60.0%, respectively. Conclusions (1) PRFA is feasible, safe and effective in treating hepatocellular carcinoma. (2) TACE is feasible, safe and effective in treating hepatocellular carcinoma. (3) Combining PRFA and TACE is feasible, safe and effective in treating hepatocellular carcinoma. The results in this study also suggests that the regimen of combining PRFA and TACE is possibly more effective than that only is treated by PRFA or TACE alone.